Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression.

IF 2.5 Q3 GENETICS & HEREDITY Epigenomes Pub Date : 2023-05-17 DOI:10.3390/epigenomes7020010
Rashmi Srivastava, Rubi Singh, Shaurya Jauhari, Niraj Lodhi, Rakesh Srivastava
{"title":"Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression.","authors":"Rashmi Srivastava, Rubi Singh, Shaurya Jauhari, Niraj Lodhi, Rakesh Srivastava","doi":"10.3390/epigenomes7020010","DOIUrl":null,"url":null,"abstract":"Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is a dynamically reversible and synchronously regulated process that orchestrates the three-dimensional epigenome, nuclear processes of transcription, DNA repair, cell cycle, and epigenetic functions, by adding or removing methylation groups to histones. Over the past few years, reversible histone methylation has become recognized as a crucial regulatory mechanism for the epigenome. With the development of numerous medications that target epigenetic regulators, epigenome-targeted therapy has been used in the treatment of malignancies and has shown meaningful therapeutic potential in preclinical and clinical trials. The present review focuses on the recent advances in our knowledge on the role of histone demethylases in tumor development and modulation, in emphasizing molecular mechanisms that control cancer cell progression. Finally, we emphasize current developments in the advent of new molecular inhibitors that target histone demethylases to regulate cancer progression.","PeriodicalId":55768,"journal":{"name":"Epigenomes","volume":"7 2","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204559/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/epigenomes7020010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is a dynamically reversible and synchronously regulated process that orchestrates the three-dimensional epigenome, nuclear processes of transcription, DNA repair, cell cycle, and epigenetic functions, by adding or removing methylation groups to histones. Over the past few years, reversible histone methylation has become recognized as a crucial regulatory mechanism for the epigenome. With the development of numerous medications that target epigenetic regulators, epigenome-targeted therapy has been used in the treatment of malignancies and has shown meaningful therapeutic potential in preclinical and clinical trials. The present review focuses on the recent advances in our knowledge on the role of histone demethylases in tumor development and modulation, in emphasizing molecular mechanisms that control cancer cell progression. Finally, we emphasize current developments in the advent of new molecular inhibitors that target histone demethylases to regulate cancer progression.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
组蛋白去甲基化酶调节:对抗癌症进展的表观遗传策略。
表观遗传修饰是控制基因功能的组蛋白或DNA的可遗传的、可逆的变化,对基因组序列本身是外源的。人类疾病,特别是癌症,经常与表观遗传失调有关。其中之一是组蛋白甲基化,这是一个动态可逆和同步调节的过程,通过在组蛋白上添加或删除甲基化基团,协调三维表观基因组,转录,DNA修复,细胞周期和表观遗传功能的核过程。在过去的几年中,可逆性组蛋白甲基化已被认为是表观基因组的重要调控机制。随着许多靶向表观遗传调控因子的药物的发展,表观基因组靶向治疗已被用于恶性肿瘤的治疗,并在临床前和临床试验中显示出有意义的治疗潜力。本文综述了组蛋白去甲基化酶在肿瘤发生和调节中的作用的最新进展,强调了控制癌细胞进展的分子机制。最后,我们强调了目前新分子抑制剂的发展,这些抑制剂靶向组蛋白去甲基化酶来调节癌症的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Epigenomes
Epigenomes GENETICS & HEREDITY-
CiteScore
3.80
自引率
0.00%
发文量
38
审稿时长
11 weeks
期刊最新文献
Environmental Factor Index (EFI): A Novel Approach to Measure the Strength of Environmental Influence on DNA Methylation in Identical Twins. Age-Dependent DNA Methylation Variability on the X-Chromosome in Male and Female Twins. Histone Modification Pathways Suppressing Cryptic Transcription. Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma. Transcription Factors Are Involved in Wizened Bud Occurrence During the Growing Season in the Pyrus pyrifolia Cultivar 'Sucui 1'.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1